undamentalytics Newsletter
Sign in

Kiniksa Pharmaceuticals International, plc balance sheet

At the end of fiscal 2025, Kiniksa Pharmaceuticals International, plc had total assets of $764m, total liabilities of $196m and shareholders' equity of $568m. It held $166m in cash against $0 of debt: net cash of $166m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents12212310818416682
Receivables41321421631
Inventory422312655108
Total current assets196243276332527750
Total assets233460526581764983
Accounts payable288224
Deferred revenue (current)——0———
Total current liabilities454764101139192
Total debt000000
Total liabilities486487142196273
Shareholders' equity185396439438568710
Net debt (negative = net cash)−122−123−108−184−166−82

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BBIO vs KNSABCRX vs KNSAIONS vs KNSAKNSA vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kiniksa Pharmaceuticals International, plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kiniksa Pharmaceuticals International, plc.